Abstract
Background: Isolated rapid-eye-movement sleep behavior disorder (iRBD) is in most cases a prodrome of neurodegenerative synucleinopathies, affecting 1% to 2% of middle-aged and older adults; however, accurate ambulatory diagnostic methods are not available. Questionnaires lack specificity in nonclinical populations. Wrist actigraphy can detect characteristic features in individuals with RBD; however, high-frequency actigraphy has been rarely used. Objective: The aim was to develop a machine learning classifier using high-frequency (1-second resolution) actigraphy and a short patient survey for detecting iRBD with high accuracy and precision. Methods: The method involved analysis of home actigraphy data (for seven nights and more) and a nine-item questionnaire (RBD Innsbruck inventory and three synucleinopathy prodromes of subjective hyposmia, constipation, and orthostatic dizziness) in a data set comprising 42 patients with iRBD, 21 sleep clinic patients with other sleep disorders, and 21 community controls. Results: The actigraphy classifier achieved 95.2% (95% confidence interval [CI]: 88.3–98.7) sensitivity and 90.9% (95% CI: 82.1–95.8) precision. The questionnaire classifier achieved 90.6% accuracy and 92.7% precision, exceeding the performance of the Innsbruck RBD Inventory and prodromal questionnaire alone. Concordant predictions between actigraphy and questionnaire reached a specificity and precision of 100% (95% CI: 95.7–100.0) with 88.1% sensitivity (95% CI: 79.2–94.1) and outperformed any combination of actigraphy and a single question on RBD or prodromal symptoms. Conclusions: Actigraphy detected iRBD with high accuracy in a mixed clinical and community cohort. This cost-effective fully remote procedure can be used to diagnose iRBD in specialty outpatient settings and has potential for large-scale screening of iRBD in the general population.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Movement Disorders |
Vol/bind | 38 |
Udgave nummer | 1 |
Sider (fra-til) | 82-91 |
Antal sider | 10 |
ISSN | 0885-3185 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:E.D. was supported by the Feldman Foundation CA. A.B.‐K. received funding for a research stay from the Stibo, Oberstløjtnant Max Nørgaard & Hustru Magda Nørgaards, Otto Mønsted, Augustinus, Knud Højgaard, William Demant, Vera & Carl Johan Michaelsens, Tranes, Marie & M.B. Richters Fond, and IDAs & Berg‐Nielsens Foundations. Funding agencies:
Funding Information:
E.D. was supported by the Feldman Foundation CA. A.B.‐K. received funding for a research stay from the Stibo, Oberstløjtnant Max Nørgaard & Hustru Magda Nørgaards, Otto Mønsted, Augustinus, Knud Højgaard, William Demant, Vera & Carl Johan Michaelsens, Tranes, Marie & M.B. Richters Fond, and IDAs & Berg‐Nielsens Foundations. E.M. was consultant for Jazz Pharmaceuticals, Sunovion, Avadel, Takeda, Eisai, Apple, Huami, Orexia, and Harmony. The remaining authors have no financial disclosures to report.
Publisher Copyright:
© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.